Pfizer's Drug Pipeline Boosts Recovery Potential, Viking Therapeutics Shows Promise
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Pfizer's Drug Pipeline: Pfizer is conducting late-stage trials for its cancer drug PF-4404, which is expected to secure approvals for multiple cancer types, thereby supporting the company's future financial performance and helping it navigate patent expirations.
- Weight Loss Drug Progress: Pfizer's acquisition of the mid-stage asset MET-097i shows promise in the weight management market, potentially providing new growth avenues and enriching its drug pipeline in a competitive landscape.
- Viking's Risks and Opportunities: Viking Therapeutics' VK2735 is under phase 3 clinical investigation, and if it successfully launches an oral version, it could address the issue of weight regain post-treatment, enhancing its market competitiveness.
- Market Attractiveness: Despite Pfizer's underperformance in 2025, its current stock price below $40 makes it appealing for long-term investors, with expectations of superior returns over the next decade.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.860
Low
24.00
Averages
28.56
High
35.00
Current: 25.860
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Revenue Rebound Potential is Significant
- Revenue Decline: Pfizer projects its 2025 revenue to be between $61 billion and $64 billion, significantly lower than the record-breaking over $100 billion in 2022, indicating challenges in revenue recovery post-COVID-19.
- Shift in Drug Development Focus: The company has struggled to prioritize other drug developments after the success of its COVID-19 vaccine, leading to slow progress in its drug pipeline and impacting overall market competitiveness.
- New Drug Market Potential: Pfizer aims to launch several new billion-dollar oncology drugs by 2030 and has entered a weight-loss drug market through its $10 billion acquisition of Metsera, which could be worth over $150 billion annually, showcasing significant future growth potential.
- Acquisitions Create New Opportunities: The acquisitions of Arena Pharmaceuticals in 2022 and Seagen for $43 billion in 2023 inject new prospects into Pfizer's pipeline, although these new drugs will not complete testing until after 2030, providing hope for future growth despite current challenges.
Continue Reading
TrumpRx Launch Delayed, Discount Drug Platform Lacks New Date
- Launch Delay: TrumpRx, initially set to launch on January 30, has been delayed with no reason provided by Endpoints News, and an updated launch date remains unknown, potentially impacting consumer access to discounted medications.
- Policy Complement: The platform is seen as a critical complement to President Trump's 'most favored nation' policy, which has already resulted in significant discounts from leading pharmaceutical companies, and its delay may hinder the effectiveness of this policy.
- Market Impact: The postponement of TrumpRx could lead to higher drug costs for consumers, particularly against the backdrop of rising medication prices, which may negatively affect the perception of the Trump administration's drug pricing policies.
- Industry Attention: Pharmaceutical companies like Eli Lilly are planning to build six large plants in the U.S., and the delay of TrumpRx may influence these companies' competitive strategies and investment decisions in the market.
Continue Reading